São Paulo, May 2021 – The Eurofarma Group, a pharmaceutical company with 100% Brazilian capital with operations in 20 countries, has for the first time neutralized 100% of its direct CO2 emissions in an unprecedented initiative in the industry. In addition to neutralizing emissions, the initiative benefits two projects – Florestas de Lábrea [Forests of Lábrea] and Redd –, created to protect the Amazon, preserve biodiversity, and support social development through the acquisition of carbon credits.

The amount invested for this acquisition will benefit social and environmental projects focused on renewable energy generation, wildlife and flora conservation, local community development, creation of job opportunities, improving medical facilities, and better quality of life for the local community.

Eurofarma values sustainable development and believes that good management of human, financial, and natural resources are key to business success. In 2020, the company added the “Action to combat climate change” SDG* to other priority SDGs it had already established and thus joined the group that reports emissions to the Carbon Disclosure Program, an important initiative of the financial industry to mitigate the effect of climate change.

As published in the company’s 2021 Sustainable Development Booklet, Eurofarma achieved this feat based on various initiatives to reduce emissions. The actions tied to direct emissions are:

• Corporate Policy for Fuel Consumption, which determines that Sales Force vehicles are supplied with 75% ethanol and 25% gasoline (this action has already reduced the fleet’s CO2 emissions by 57%); 
• Solidarity Ridesharing, with exclusive parking spaces for those who share transportation and for electric or low-emission vehicles;
• Smart Fleet – the company started to replace the entire fleet of executive cars with hybrid vehicles. Altogether, 52 vehicles have already been replaced, with 153 expected by 2023;
• Eco Bike Program, which provides employees at the Itapevi Unit (SP) with common, cargo, and electric bikes for internal use. In all, there are 8 stations in the complex. The initiative promotes environmental awareness and encourages physical activity.

The actions related to indirect emissions are:

• Renewable energy sources, with a robust photovoltaic power generation system at the Itapevi Unit (São Paulo), which has more than 7,200 solar panels on the roofs of buildings, with 2.2 MW of installed power;
• Zero Landfill: Implementation of the composting process began in 2018 and is currently active in all of the company’s operations. In 2020 the company reduced emissions by eliminating waste transportation for external treatment;
• Raízes [Roots] Program: The Itapevi Unit (São Paulo) also houses the Raízes [Roots] Program, which honors employees who have been with the company for 15 years. Said employees are invited to plant a native tree in the Complex, and Eurofarma records their name, the tree species, and the date of planting.  The action reinforces the environmental commitment and maintains a wide conservation area. In all, the Raízes [Roots] Program has already given us 650 trees. 

Since 2008, Eurofarma’s inventory of greenhouse gas (GHG) emissions has been following the GHG Protocol methodology by reporting the emissions of gases controlled by the Paris Agreement. This inventory allows mapping the sources of GHG emissions of an activity, process, organization, economic sector, city, state, or even country, followed by the quantification, monitoring, and recording of those emissions.

*SDGs – Sustainable Development Goals, established by the UN (United Nations)

About Eurofarma Group 
As the first multinational pharmaceutical enterprise with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 433 products, over 1,000 dosage forms, and covers 30 medical specialties and 201 therapeutic classes, accounting for 66% of the market.

The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported net sales totaled BRL 5.7 billion in 2020 and the Group employs over 7,600 people.

Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | Twitter: @eurofarma
YouTube: @eurofarmalab